The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988

Hornsten, P.

doi:10.1001/archderm.126.7.919

Cited by 27 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agranulocytosis was a rare ADR of dapsone,6 but a severe and unpredictable idiosyncratic reaction. It has been reported that agranulocytosis occurs in 0.23–0.42% of dermatitis herpetiformis patients treated with dapsone 7. Agranulocytosis led to perianal abscess and death of a Japanese woman due to septic shock 17.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study

Guragain¹,

Upadhayay²,

Bhattarai³

2017

CPAA

View full text Add to dashboard Cite

ObjectiveTo investigate the occurrence and clinical characteristics of dapsone-related adverse drug reactions (ADRs) among leprosy patients who underwent multidrug therapy (MDT) from 2010 to 2013 in the western region of Nepal.MethodsA retrospective review was carried out in the rehabilitation center. Data were collected from the record files of the hospital.ResultsFrom 2010 to 2013, there were 18 patients reported to have dapsone ADRs, with an occurrence rate of 0.82% in the 4-year duration. The maximum incidence of ADRs (1.043%) was in 2010 and the minimum incidence of ADRs (0.26%) was in 2013. Among two types of bacterial infections, 94.44% were of multibacillary and 5.56% were of paucibacillary type. The age range of patients with dapsone ADRs was 11–68 years. The male-to-female ratio was 1.25. The onset of dapsone ADRs after taking MDT was within a minimum of 3 weeks and a maximum of 21 weeks. There were 14 (77.77%) patients who presented with jaundice, 8 (44.44%) with exfoliative dermatitis, 5 (27.77%) with hemolytic anemia and 4 (22.22%) with fever and headache. The rare side effects (5.5%) found were agranulocytosis or toxic epidermal necrolysis. Three patients were cured; some were still on the treatment. Four patients died with dapsone ADRs.ConclusionThe common dapsone ADRs present in leprosy patients were jaundice, exfoliative dermatitis and hemolytic anemia in MDT-treated patients. Patients could be cured by managing the dapsone ADRs effectively on time. Some patients may die of dapsone ADRs if clinicians fail to manage the side effects on time.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It has been reported that agranulocytosis occurs in 0.23–0.42% of dermatitis herpetiformis patients treated with dapsone 7. The other rare effects of dapsone are bone marrow suppression and peripheral pancytopenia 8…”

Section: Introductionmentioning

confidence: 99%

Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study

Guragain¹,

Upadhayay²,

Bhattarai³

2017

CPAA

View full text Add to dashboard Cite

show abstract

“…It is thought that dapsone interferes with integrin-mediated neutrophil adherence and G protein-mediated signal transduction for neutrophil recruitment [18,19,20]. The antioxidant properties of dapsone are likely exerted through the inhibition of myeloperoxidase, resulting in reduced reactive oxygen species.…”

Section: Discussionmentioning

confidence: 99%

“…Despite a sulfone moiety, patients with sulfa allergies may tolerate dapsone, but previous allergic reactions must be considered, as demonstrated by Strom et al [25]. Agranulocytosis has been found to develop at a higher rate in patients receiving dapsone for dermatitis herpetiformis compared to patients treated for leprosy [19]. It is hypothesized that the development of agranulocytosis is dependent on many risk factors, possibly including immune status, drug dosage and ethnic origin [20].…”

Section: Discussionmentioning

confidence: 99%

Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature

Sheu¹,

Divito²,

Enamandram³

et al. 2015

Dermatology

View full text Add to dashboard Cite

Background: Pustular psoriasis is an uncommon psoriasis variant, clinically characterized as small sterile pustules on an erythematous base. Evidence for therapy is lacking, and many currently employed systemic therapeutics carry risks of significant side effects, without specifically targeting disease etiology which includes the aggregation of neutrophils. Observations: We report therapy with the anti-neutrophil agent dapsone in 5 patients with pustular psoriasis and provide a brief review of the literature. Four patients responded to oral dapsone and 1 to topical dapsone therapy. All 5 patients had previously failed multiple topical and systemic treatments. In 2 cases, oral dapsone allowed for the discontinuation of other systemic agents. One patient stopped oral dapsone due to a side effect of sleep disturbance. Conclusion: Dapsone has a much safer side effect profile and may target the pathophysiology of pustular psoriasis more directly than many other systemic agents. As such, dapsone should be considered for the treatment of patients with pustular psoriasis.

show abstract

“…[1] Although only rarely reported in leprosy,[2] it may prove lethal and should always be on the alert clinician's radar while treating this common tropical infection.…”

mentioning

confidence: 99%

Dapsone-induced neutropenia with invasive pulmonary aspergillosis

2012

View full text Add to dashboard Cite

The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988

Cited by 27 publications

References 0 publications

Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study

Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study

Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature

Dapsone-induced neutropenia with invasive pulmonary aspergillosis

Contact Info

Product

Resources

About